Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis

Minimally important difference estimates and methods: a protocol

(2015) Bradley C Johnston et al.   BMJ Open

Interferon-beta-1a treatment has a positive effect on quality of life of relapsing–remitting multiple sclerosis: Results from a longitudinal study

(2014) Francesco Patti et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Health related quality of life in patients recently diagnosed with multiple sclerosis

(2013) G. Klevan et al.   ACTA NEUROLOGICA SCANDINAVICA

Work capacity and health-related quality of life among individuals with multiple sclerosis reduced by fatigue: a cross-sectional study

(2013) Gullvi Flensner et al.   BMC PUBLIC HEALTH

Predictors of quality of life among multiple sclerosis patients: a comprehensive analysis

(2013) B. Yamout et al.   EUROPEAN JOURNAL OF NEUROLOGY

Health-related quality of life as an independent predictor of long-term disability for patients with relapsing-remitting multiple sclerosis

(2013) K. Baumstarck et al.   EUROPEAN JOURNAL OF NEUROLOGY

How People with Multiple Sclerosis Rate Their Quality of Life: An EQ-5D Survey via the UK MS Register

(2013) Kerina H. Jones et al.   PLoS One

Impaired health-related quality of life predicts progression of disability in multiple sclerosis

(2012) J. Benito-León et al.   EUROPEAN JOURNAL OF NEUROLOGY

Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study

(2012) Judith J Stephenson et al.   Health and Quality of Life Outcomes

Cognitive impairment, health-related quality of life and vocational status at early stages of multiple sclerosis: a 7-year longitudinal study

(2012) Aurélie Ruet et al.   JOURNAL OF NEUROLOGY

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

(2012) Jeffrey A Cohen et al.   LANCET

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

(2012) Alasdair J Coles et al.   LANCET

Alemtuzumab more effective than interferon  -1a at 5-year follow-up of CAMMS223 Clinical Trial

(2012) A. J. Coles et al.   NEUROLOGY

Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study

(2011) X Montalban et al.   Multiple Sclerosis Journal

The impact of increasing neurological disability of multiple sclerosis on health utilities: a systematic review of the literature

(2010) Huseyin Naci et al.   JOURNAL OF MEDICAL ECONOMICS

Employment in multiple sclerosis

(2008) L. J. Julian et al.   JOURNAL OF NEUROLOGY

Self-rated physical health predicts change in disability in multiple sclerosis

(2008) J Drulovic et al.   Multiple Sclerosis Journal

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

(2008)   NEW ENGLAND JOURNAL OF MEDICINE